ETF Resumé

PBETicker Symbol

PowerShares Dynamic Biotech &Genome ETFFund

 

43.88

  • Change 0.81 (1.9%)
  • Volume 0.05 M

4:00 PM EDT Jul 29, 2014
U.S. Markets are closed

  • Assets $381.3M
  • Expense Ratio 0.63%
  • Yield 2.17%
  • Vs 50 Day EMA %
  • Vs 200 Day EMA %

US Equity ETF

PowerShares Dynamic Biotechnology & Genome Portfolio is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the price and yield of the Dynamic Biotechnology & Genome Intellidex Index a fundamentally-weighted index. Securities shown to possess the greatest capital appreciation potential are selected by the Index.

Performance
TODAY 1 DAY 5 DAY 10 DAY 1 MO 3 MO 6 MO 1 YR 2 YR 5 YR
1.9% 1.9% 2.7% 3.3% 0.2% 11.5% 7.5% 35.6% 84.5% 172.2%
Last Close Volume
AVG VOL (10 D) CHANGE
52,489 -10.3%
Trend on Last Close
  Price EMA EMA P DATE CROSSED
50 DAY 43.88 42.52 3.2% 07-18-2014
200 DAY 43.88 39.72 10.5% 12-31-2012
Technical
ALPHA BETA R2 STD DEV
0.0066 1.006 0.473 0.059
Copyright © 2011 QuoteMedia.  Data delayed 15  minutes unless otherwise indicated (View delay times for all exchanges).   RT = Realtime,  DL+ = Realtime BATS,  EOD = End Of Day,  PD = Previous Day.  
Market Data powered by QuoteMediaTerms of Use.

stock information
  • Most Searched ETFs: Surging Sectors

    06-14-2014 08:00 AM by Todd Shriber

    U.S. stocks managed to closer higher Friday, but in a case of June gloom, the S&P 500 snapped a multi-week winning streak. Escalating tensions at the hands of a militant faction of al-Qaeda in Iraq weighed on stocks, but sent oil prices soaring. On that note, it is surpris...

    Read more

  • The Biotech ETF Rally No One is Talking About

    06-09-2014 01:25 PM by Todd Shriber

    Perhaps it is just the way the media operate, an unfortunate byproduct of people paying ample attention to negative news or both, but there is a rally going on in biotechnology stocks and exchange traded funds that is receiving scant attention. From its March 4th peak to its A...

    Read more

  • Why These Two Biotech ETFs Are Soaring Monday

    06-09-2014 12:09 PM by Tom Lydon

    The PowerShares Dynamic Biotechnology & Genome Portfolio (NYSEArca: PBE) and the SPDR S&P Biotech ETF (NYSEArca: XBI) are up 8.4% and 6.8%, respectively, Monday, making the duo the day's two best non-leveraged ETFs. PBE and XBI are soaring because the two ETFs feature ...

    Read more

  • More Upside Possible for Biotech ETF

    05-06-2014 12:46 PM by Todd Shriber

    From its Feb. 25 to its April 14 lows, the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) tumbled 21.2%. That fits the definition of a bear market and IBB's decline, along those of the other biotech ETFs, received ample attention due in large part to talk that the biotech se...

    Read more

  • Biotech Bumble: ETFs Fall to 2014 Lows

    04-10-2014 02:16 PM by Todd Shriber

    More bad price action out of the biotechnology sector Thursday and that underscores the precarious technical conditions being faced some exchange traded funds that were beloved just several weeks ago. Here is a brief recap of just how bad biotech stocks and ETFs have been sinc...

    Read more

  • Investors Say Bye-Bye to Biotech ETFs

    04-08-2014 12:45 PM by Todd Shriber

    It has been said, and it is more often than not true, that flows data for exchange data is not a predictor of future performance, but rather a sign of investors chasing past performance. When it comes to once beloved biotechnology ETFs, it is not debatable that the group's rec...

    Read more

  • Big Biotech ETF Still in Uptrend…For Now

    03-26-2014 08:15 AM by Tom Lydon

    The subject has been talked to death over the past week, but that does not mean attention on the biotech sector is waning. Amid increased talk of a biotech bubble and fears of government-controlled pricing, biotech stocks and exchange traded funds have been under siege in rece...

    Read more

  • Health Care ETFs Raking in Plenty of Cash

    03-06-2014 11:54 AM by Todd Shriber

    On the surface, it would appear that equity-based exchange traded funds are struggling to keep and attract assets this year. Inflows to equity ETFs do not look poised to recapture last year's magic. Even when backing out the $17.4 billion lost by the SPDR S&P 500 (NYSEArca...

    Read more

  • Why This Biotech ETF Leads the Pack

    02-21-2014 08:15 AM by Todd Shriber

    There are five biotechnology exchange traded funds on the market today. Confirming just how strong the sub-sector has been this year three of those ETFs – the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT), the Market Vectors Biotech (NYSEArca: BBH) and the iShare...

    Read more

  • Health Care Heaven: Sector’s ETFs Flex Their Muscles

    02-14-2014 08:00 AM by Todd Shriber

    Forty-seven exchange traded funds hit all-time highs on Thursday. In a testament to the ongoing strength of the health care sector, now the third-largest in the S&P 500, 16 of the ETF's touching all-time highs yesterday were health care funds. This is not a new phenomenon....

    Read more

  • The One ETF Really Benefiting From the Intercept Pharma News

    01-09-2014 01:57 PM by Todd Shriber

    No need to do a double take with the following because it is true: Shares of Intercept Pharmaceuticals (NasdaqGM: ICPT) are up $210, or a tidy 290%, after trials for the company's liver disease treatment proved successful. That is good news for the biotechnology sector, which ...

    Read more

  • Intense Duel to be 2013’s Best Health Care ETF

    12-23-2013 08:00 AM by Tom Lydon

    This has been, quite simply a very, very good year in which to be long health care exchange traded funds. The Health Care Select Sector SPDR (NYSEArca: XLV) is battling with its discretionary rival to be the best of the nine SPDR ETFs for 2013 and XLV spent some time as the th...

    Read more

  • Biotech ETFs: More Tricks Than Treats in October

    10-31-2013 02:45 PM by Max Chen

    Biotech exchange traded funds, market leaders for much of this year, stumbled in October as the government shutdown had an unexpectedly debilitating affect on the high-flying sub-industry. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks large biotech or phar...

    Read more

  • Sell-Off in Biotech ETFs Could Be a Temporary Setback

    10-10-2013 07:30 AM by Tom Lydon

    Biotechnology exchange traded funds are on a three-day sell-off after falling short of its 52-week high Friday, but the sector can still find its footing. The he iShares Nasdaq Biotech (NasdaqGM: IBB) has declined 7.5% in the past three sessions, Market Vectors Biotech ETF (NY...

    Read more

  • 10 ETF Investments That Got the Most Bang for Your Buck

    10-08-2013 01:14 PM by Tom Lydon

    Riding out tax hikes, interest rate risk and geopolitical tensions, the broad equity markets touched historic highs this year, with alternative energy, biotech and technology stock exchange traded funds leading the pack. In the technology space, social media stocks are experie...

    Read more

  • Three ETFs to Play Up-and-Coming Health Care Companies

    09-03-2013 04:10 PM by Tom Lydon

    Rummaging through small-cap biotechnology companies, investors can pick out the next break-through drug provider, but it also leaves you exposed to potential flubs. Instead, exchange traded funds offer diversified basket to the growing sector. "The jarring pace of change, sing...

    Read more

  • Three ETFs to Play the Outperforming Biotech Sector

    08-19-2013 04:39 PM by Tom Lydon

    The biotechnology sector has been one of the best performing areas in the market this year. While investors can try to bet big, and potentially lose big, on biotech stocks, an exchange traded fund helps diversify risk with a basket of securities. "The jarring pace of change, s...

    Read more

  • Choosing the Right Biotech ETF Exposure

    04-20-2012 03:09 PM by Tom Lydon

    Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash a...

    Read more

  • Biotech ETFs Mixed After Gilead Subpoena

    06-13-2011 01:53 PM by Tom Lydon

    Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice. Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday...

    Read more

  • 5 Biotechnology ETFs to Play Innovation

    02-22-2011 02:00 PM by Tom Lydon

    While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector. Currently, the bi...

    Read more

  • Why Health Care ETFs May Be In the Clear

    11-10-2010 11:00 AM by Tom Lydon

    After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don't believe there's anything to worry about for a while. First, with most corporations backi...

    Read more

  • 5 Things That Drive Biotech ETFs

    10-21-2010 03:00 PM by Tom Lydon

    The biotechnology sector is a unique one because many of the companies that compose it are not yet profitable. Here's what drives the sector and exchange traded funds (ETFs) that let you play it. Kashif Javed for Forex Trading Analysis reports that the biotech sector is driven...

    Read more

  • Biotech ETFs:The Better Way to Play

    10-11-2010 06:00 AM by Tom Lydon

    As cash-strapped biotech companies see their cash reserves dwindle, it  has forced a number of companies to close up shop. The struggles faced in the sector highlights the benefits of getting exposure to it through biotech exchange traded funds (ETFs). The number of publicly-t...

    Read more

  • Biotech ETFs: 5 Ways to Play Innovation

    08-08-2010 01:00 PM by Tom Lydon

    Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) ...

    Read more

  • 5 Biotech ETFs If You're Bullish

    06-25-2010 01:00 AM by Tom Lydon

    Biotechnology has helped improve the lives of many people. Naturally, many biotech stocks boom or bust based on the success of products in their pipeline. But if you're looking for a more diversified and steady approach to biotech investing, look no further than exchange traded f...

    Read more

  • Biotech ETFs: Where the Future Lies

    02-05-2010 02:00 PM by Tom Lydon

    Biotechnology is continuously advancing and the future may lie in personalized medicine. The biotech sector, along with related exchange traded funds (ETFs), may see billions in revenue as this market grows in the coming years. Biotech companies, investors, providers and big p...

    Read more

  • Biotechnology: Why ETFs Suit the Sector

    11-19-2009 02:00 PM by Tom Lydon

    The biotechnology sector is once again finding its footing, with some exchange traded funds (ETFs) focused on the sector up more than 30% since the market's March 9 low. But there have been stumbling blocks on the way back to profitability. A reputable biotechnology company h...

    Read more

  • What Biotechnology ETFs Need to Thrive

    09-04-2009 02:00 PM by Tom Lydon

    The biotechnology sector and its related exchange traded funds (ETFs) have seen a handsome rebound off the March 9 lows, but does the cash-strapped sector have what it takes to survive for the long haul? Analysts estimate that nearly half of all biotechnology firms have insuf...

    Read more

  • 7 Reasons Biotechnology ETFs Could Succeed

    08-06-2009 01:00 AM by Tom Lydon

    The biotechnology sector and exchange traded funds (ETFs) have had a good summer so far. Some funds are up as much as 22% in the last month alone. Will it continue? July was kind to the biotech sector. The NYSE Biotechnology Sector rose up 24%, which dwarfed the 6% for the S&a...

    Read more

  • ETF Spotlight: PowerShares Dynamic Biotech & Genome (PBE)

    07-29-2009 02:00 PM by Tom Lydon

    ETF Spotlight on PowerShares Dynamic Biotech & Genome (PBE), part of a weekly series. Assets: $148 million Holdings: This fund invests in companies involved in the biotechnology and genome sectors. Some of the top components include ImmunoGen (IMGN), Amgen (AMGN), Gilead S...

    Read more

  • Biotech Sector and ETFs Get a Lifeline

    07-08-2009 12:00 PM by Tom Lydon

    A small piece of the 2009 Economic Stimulus Package will revamp aid to small businesses, which could give way to successful relationships between  small pharmaceutical/biotech companies and academic institutions. This may be what related investments and exchange traded funds (ET...

    Read more

  • Health Care Reform and Biotech ETFs: Will There Be Opportunities?

    06-27-2009 01:00 AM by Tom Lydon

    In an attempt to reduce costs in the health care industry, the government will be legislating for cheaper drugs, but drug makers, along with related exchange traded funds (ETFs), may see profits slip away. The Obama administration claims that biologic drugs should be subject t...

    Read more

  • Why Biotech ETFs May Be the Better Choice

    06-17-2009 11:00 AM by Tom Lydon

    Biotechnology stocks present opportunities, but given the unique challenges of the sector, exchange traded funds (ETFs) may be the better route to go if you're considering making an investment. Owning individual biotechnology companies can be a challenging way to invest in th...

    Read more

  • Can Obama's Push Reignite Biotech and Health Care ETFs?

    06-15-2009 12:00 PM by Tom Lydon

    Biotechnology and health care-related exchange traded funds (ETFs) could be set to take off as both sectors are in a transition period  and are gaining more support from the Obama administration. President Barack Obama today met with the American Medical Association about his...

    Read more

  • Health Care ETFs' $140 Billion Boost

    02-19-2009 06:00 AM by Tom Lydon

    When President Barack Obama put his John Hancock on the $787 billion stimulus package, $140 billion of it was related specifically to fixing health care and, in turn, related exchange traded funds (ETFs). What's in the bill? A provision to help workers who lose their j...

    Read more

  • PowerShares' ETF Family Grows With Biotech, Commodities

    09-18-2008 12:00 PM by Tom Lydon

    The PowerShares exchange traded fund (ETF) family is adding a slew of new members this week. The PowerShares Global Biotech Portfolio (PBTQ) covers the growth of this industry. The biotech industry has seen increasing growth and revenue base over the past two years. No single ...

    Read more

  • Biotech ETFs Are a Matter of Personal Choice

    07-27-2008 01:00 AM by Tom Lydon

    Biotechnology appeals to many investors, and with four different exchange traded funds (ETFs) focused on the class, is there a fund that is better than the rest? The sector is one of the few non-commodity related that's solidly above its trend line. Each of the four ETFs wi...

    Read more

  • Biotechnology ETFs Growing...Like Genetically Modified Crops?

    07-16-2008 11:00 AM by Tom Lydon

    Biotechnology is the non-commodity exchange traded fund (ETF) area du jour, it seems. In a time where the markets seem bleak, the sector is delivering a ray of light. Genentech (DNA) this week upped its 2008 forecast, and also said its second-quarter profit rose 4.7%, thanks t...

    Read more

Loading...

Loading...

Number of Holdings: 30

Technology 83.3%
Specialty Chemicals 5.7%
Life Sciences Tools & Services 5.3%
Medical Supplies 2.9%
Scientific Instruments: Control & Filter 2.8%
Biotech 57.3%
Life Science Equipment 25.3%
Specialty Pharmaceuticals 9.2%
Specialty Chemicals 5.7%
Industrial Machinery Mfg 2.4%
Unknown 0.1%
United States 100%
Large-cap 35.8%
Mid-cap 30.7%
Small-cap 23.5%
Micro-cap 10%

Number of Holdings: 30

%

Ticker

Name

Sector

Market Cap

Country

9.5% IDIX Idenix Pharmaceutica... Technology 3642870000 United States
4.9% GILD Gilead Sciences Inc Technology 134986460000 United States
4.8% ILMN Illumina Inc Technology 23479220000 United States
4.7% AMGN Amgen Inc Technology 92212810000 United States
4.7% WAT Waters Corp Scientific Instruments: Control & Filter 8972220000 United States
4.7% BIIB Biogen Idec Inc Technology 78413510000 United States
4.5% ALXN Alexion Pharmaceutic... Technology 32559270000 United States
4.4% REGN Regeneron Pharmaceut... Technology 31390000000 United States
2.9% PCYC Pharmacyclics Inc Technology 7074020000 United States
2.8% ITMN InterMune Inc Technology 4394370000 United States

Members see all holdings. Not a member yet? Click here to join.